FCGR3A and neoplasm: This bispecific VHH was shown to trigger activation of CD16+ NK cells, resulting in enhanced cytotoxicity of EGFR+ tumor cell lines and EGFR+ patient CRC specimens in both an autologous and allogeneic setting.